Parol tablets

Form: Tablets
Dosage: 500mg
Packaging: 30 oral tablets

Active substance: paracetamol

Form: Tablet

Dosage: Each tablet 500 mg of paracetamol

Packaging: Box with 30 tablets

 

Target: Adults and children (<6 years)

 

Parol tablets are not indicated for children under the age of 6 years. If necessary, Parol Suspension, a drinkable paracetamol suspension is available.

Parol is indicated for the relief of mild to moderate pain and for the reduction of fever.

Parol® tablets are used for the symptomatic treatment of acute and chronic pain: headaches, toothache, dysmenorrhea, migraine, myalgia, neuralgia, post-traumatic pain, post-operative pain and musculoskeletal pain.

Parol can also be used as an antipyretic and painkiller for flu, colds, sore throats, sinusitis, and other acute febrile conditions.

  • Adults: 1 to 2 tablets up to 3 times a day.
  • Children 12 years and older: 1 tablet up to 3 times daily.
  • Children 6 to 12 years: 1/2 to 1 tablet up to 3 times a day

Over-the-counter drug

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma